Press releases
- Hansa Biopharma: increase in number of shares and votes
- Hansa Biopharma interim report January-March 2024
- Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
- Hansa Biopharma publishes 2023 Annual and Sustainability Reports
- Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer
More ▼
Key statistics
As of last trade, Hansa Biopharma AB (24H:DEU) traded at 2.61, 52.51% above the 52 week low of 1.71 set on Oct 16, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.60 |
---|---|
High | 2.62 |
Low | 2.51 |
Bid | 2.61 |
Offer | 2.67 |
Previous close | 2.61 |
Average volume | 200.00 |
---|---|
Shares outstanding | 63.15m |
Free float | 59.05m |
P/E (TTM) | -- |
Market cap | 1.93bn SEK |
EPS (TTM) | -16.07 SEK |
Data delayed at least 15 minutes, as of May 09 2024.
More ▼